cyrilzakka/clinical-trials huggingface dataset:
French Observatory on Hospitalizations in Cardiology of Patients of 80 Years and Over

Because of increased life expectancy and improved therapeutic methods in cardiology, the proportion of very old patients with cardiovascular disease increases. However, clinical practice "in real life" are still insufficiently known in this population. The recommendations still lack of studies specifically devoted to elderly or very elderly, an extrapolation of data based on evidence obtained in younger populations.

This is a multicenter observational study during a day. On this day, all participating centers fill a questionnaire for each patient 80 years or older hospitalized in their service.

Information about the center will be collected: non-university or university center, presence of coronary angiography room, number of beds, number of patients 80 years or older hospitalized in the day of the investigation.

The questionnaire is designed to:

* Know the history of cardiovascular and noncardiovascular patient and degree of dependence
* Know the reason for hospitalization
* Evaluate the diagnostic and therapeutic already implemented or planned for this patient

The day of the survey, information on each patient 80 years or older hospitalized in the service will be collected:

* Patient Data: date of birth, sex, status. The patient identification data (name, surname, address) will not be collected.
* Patient History: date of last hospitalization, life, cardiovascular risk factors, cardiovascular and non cardiovascular history, date of last hospitalization, life
* Circumstances of admission: course of care before admission, admission to intensive care unit or hospital unit classical primary diagnosis and diagnosis (s) partner (s)
* Initial assessment: treatment admission, major hemodynamic, electrocardiographic and biological
* Regarding the current hospitalization: diagnosis already implemented or planned (echocardiography, angiography, electrophysiological study, etc ...), therapeutic methods already implemented or planned angioplasty, percutaneous valve intervention, conventional or biventricular stimulation, cardiac surgery, medication
* Become of the patient after hospitalization
* The clinician's subjective impressions about the condition of the patient and monitoring recommendations
* Assessment of addiction: ADL Scale

No monitoring of patients is contemplated.

Eligibility Criteria:
Inclusion Criteria:

* Patient aged 80 years or more
* Patient present in a cardiology service in the morning (8:00 to 12:00) the day of the survey
* Admission to the service took place on the survey day or in the 15 days preceding the survey.

Exclusion Criteria:

* Patient with age \<80 years.
* Patient who have expressed a refusal to participate in the study
The Elite Athlete Mental Health Strategy Trial

The purpose of this study is to determine whether positive mental health help-seeking attitudes, and behaviour in elite athletes can be increased through an online intervention.

Mental disorders account for approximately 30% of the non-fatal disease burden in Australia, with the most prevalent disorders of depression, anxiety and substance use disorders experienced by 18% of the population in any single year. These disorders are significantly more common in young adulthood than at any other stage in the lifespan. Despite the availability of effective treatments for many disorders, this high susceptibility in young people is coupled with low rates of seeking professional help. As elite athletes have been found to have less positive attitudes towards seeking help for mental health issues, and they are most often young adults themselves, they may be even less likely than non-athletes to utilise professional services. Although there is a strong relationship between exercise and positive mental health, the prevalence of mental disorders in elite athletes is currently not known. A literature review of the general literature on help seeking and a series of focus groups with elite athletes from the Australian Institute of Sport conducted by the current research group in 2008, suggested that help-seeking by these athletes might be increased by improving their knowledge about mental health, reducing stigma, and providing feedback about the symptoms of common mental disorders.

The current project was designed to test these possibilities utilising an online format. The Elite Athlete Mental health Strategy (TEAMS) project comprises two phases: (1) a large scale survey of the mental health status of elite athletes; (2) a randomised controlled trial of the effectiveness of three interventions designed to increase help seeking attitudes and help seeking behaviours related to mental disorders in elite athletes. These three interventions are: destigmatisation and mental health literacy; feedback; and a help-seeking list of resources. The study aims to compare the effectiveness of these three interventions relative to each other and a control condition.

Eligibility Criteria:
Inclusion Criteria:

* Invited through sports organisation
* Elite athlete
* Able to read English

Exclusion Criteria:

* None.
Dual Guidance in Regional Anesthesia

Regional anaesthesia is a frequently used procedure. Currently, blockades are increasingly carried out without nerve stimulation. The risk of nerve lesion is about 3 %. Industrial efforts frequently referred to ultrasound optimisation of the regional anaesthesia cannula. In order to optimise patient safety, the benefit of both procedures (stimulation and ultrasound) should be combined and both procedures optimised. In this study, the influence of the needle electrode size on the stimulability of the nerve ischiadicus should be determined.

There are various methods of performing regional anesthesia. In recent years, the focus has been on ultrasound-supported regional anaesthesia, and the stimulation methods that were often used in the past were no longer used or used less frequently. The combination of both methods may be an additional safety aspect and can contribute to an improved blocking quality. In addition to the best possible ultrasound quality, an optimal stimulation quality is also required. The investigators plan to carry out dual-guidance blockages of the ischiadic nerve with various regional anaesthesia needles (manufacturer of the used needles: Pajunk Medical Produkte GmbH, Geisingen, Germany; Teleflex Medical GmbH, Kernen, Germany). All regional anaesthesia cannulae are approved for the planned blockades of humans in Germany.

Eligibility Criteria:
Inclusion Criteria:

* Presence of the written declaration of consent
* Age of at least 18 years
* No participation in another intervention study during participation

Exclusion Criteria:

* present contraindication for the application of regional anesthesia and nerve stimulation
* Cardiac pacemaker/AICD (Automated internal cardioverter defibrillator) carrier
* Known allergies to used medicines
* Patients under 18 years of age
* Ineligible patients
* Missing consent
* Pregnancy/nursing patients
* Classification of patients into class 4 or higher status according to the American Society of Anesthesiologists
* Existing nerve damage in the target area
* Medically treated diabetes mellitus, alcohol abuse or alcohol abuse in the patient's history (using AUDIT)
* Visibility score of the nerve of 3 or more
* Participation in another intervention study during participation
* Accommodation in an institution on the basis of a court or administrative order
An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed.

   \[ Designated as safety issue: No \]
2. In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients.

\[ Designated as safety issue: No \]


Eligibility Criteria:
Inclusion Criteria:

Patients will be included when they meet the following criteria:

1. 18 years of age or older.
2. Ability and willingness to provide signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation.
3. Patients on stable therapy with Trizivir only (or its equivalent component drugs), for at least 6 months prior to screening.
4. Patients with plasma HIV-1-RNA \<=50 copies/mL documented on at least two occasions within 6 months prior to enrollment.
5. Documentation of plasma HIV-1 RNA of \<=50 copies/mL for \>=6 months while on Trizivir without other antiretroviral agent. Documentation will include dates and results of all viral load testing from the previous six months.
6. Ability and willingness to complete the study.

Exclusion Criteria:

Patients will not be included when they meet one or more of the following criteria:

1. Previous exposure to NNRTI drugs.
2. Documented diabetes mellitus.
3. Documented hypertension (systolic \>155 mmHg and/or diastolic \>95 mmHg).
4. Fasting hypertriglyceridemia (\>5.6 mmol/L or 500 mg/dl).
5. Use of lipid-lowering medication during the 90 days prior to study enrollment.
6. Chronic active hepatitis B and/or C infection by history.
7. Anemia (Hb \<7.0 mmol/l or 11 g/dl hematocrit \<32%).
8. Active opportunistic infection or neoplasm within 3 months prior to screening visit with the exception of cutaneous Kaposi's sarcoma without evidence of progressive disease.
9. Any history of cardiovascular disease (infarction, heart failure, peripheral vascular disease, cerebrovascular disease).
10. Hepatic, renal or thyroid abnormalities, as determined significant by the Principal Investigator.
11. Pregnancy or lactation.
12. Active anticoagulation therapy (coumarin derivates, heparin).
13. History of HIV-2 infection.
14. Female patients with CD4 counts \>250 cells/mm3.
15. Male patients with CD4 counts \>400 cells/mm3. Others which can not be listed here.
Large Sample PD Patients and Healthy Controls

Resting-state functional magnetic resonance imaging (RS-fMRI) has frequently been used to investigate local spontaneous brain activity in Parkinson's disease (PD) in a whole-brain, voxel-wise manner. To quantitatively integrate these studies, we conducted a coordinate-based meta-analysis on 15 studies that used amplitude of low frequency fluctuation (ALFF) and 11 studies that used regional homogeneity (ReHo). All these ALFF and ReHo studies have compared PD patients with healthy controls. We also performed a validation RS-fMRI study of ALFF and ReHo in a frequency-dependent manner for a novel dataset consisting of PD and healthy controls.

Seed-based d Mapping (formerly Signed Differential Mapping, SDM) software (version 5.141 for Windows) (www.sdmproject.com) was used for meta-analysis.

For the validation, fMRI data were acquired on a 3 Tesla Magnetic Resonance scanner (Trio system; Siemens Magnetom scanner, Erlangen, Germany) with gradient-echo echo-plannar imaging sequences. Whole brain fMRI scanning was carried out. All participants were instructed to keep their eyes closed, relax, remain motionless, not think of anything in particular, and not fall asleep. Foam pads were used to minimize head motion.

Eligibility Criteria:
Inclusion Criteria:

* The PD diagnoses were based on the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria. Patients were assessed using the UPDRS III and Hoehn and Yahr disability scale.

Exclusion Criteria:

* 1. history of head trauma, 2. substance abuse, 3. psychiatric disorder. For healthy controls, additional exclusion criteria included

  1. any history of neuropsychiatric disorders.
Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II

Hypercholesterolemia is a well-established risk factor for the development of atherosclerosis, a component of cardiovascular disease (CVD). The National Cholesterol Education Program advises the public to consume 2 g/day of plant sterols or stanols in addition to the Therapeutic Lifestyle Change Diet to lower elevated low-density lipoprotein (LDL) cholesterol levels. For foods to carry the FDA health claim label they must contain 0.65 g of phytosterol ester or 1.7 g of phytostanol ester per serving. The study was a controlled diet, cross-over clinical investigation using a Latin square sequence. It consisted of two 29 d phases separated by a four week wash out interval. Subjects were randomized to one of two treatment arms: 1 % dairy milk or low-fat soy beverage providing 1.95 g plant sterols/day.


Eligibility Criteria:
Inclusion Criteria:

1. Healthy males and females, age 19-60 years old, will be screened for determination of fasting circulating LDL-cholesterol and triglyceride (TG) levels.
2. Subjects accepted into the study will have plasma LDL-C levels between 120 and 200 mg/dl, TG levels below 250 mg/dl, and a body mass index (BMI) between 22 to 32 kg/m2.
3. Subjects must also demonstrate an ability to understand dietary and exercise procedures and be judged as compliant and motivated by the investigators.
4. Subjects will be permitted to take stable doses of thyroid hormone and anti-hypertensive agents, as long as these are continued equivalently throughout the duration of study.

Exclusion Criteria:

1. History of recent (i.e. less than 3 mo) or chronic use of oral hypolipidemic therapy, including fish oils, or probucol within the last 6 months.
2. History of chronic use of alcohol (\>2 drinks/d), systemic antibodies, corticosteroids, androgens, or phenytoin.
3. Myocardial infarction, coronary artery bypass, or other major surgical procedures within the last six months.
4. Recent onset of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, diabetes, or significant current (ie. onset within past three months) gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year).
5. Exercise greater than walking or running 15 miles/wk or 4,000 kcal/week.
Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy

The goal of the study is to evaluate two 6-month adjunct interventions (peer mentorship and social support mentorship) for individuals with eating disorders. Individuals will be randomized to peer-mentorship, social support mentorship, or a wait-list and eating disorder symptoms will be evaluated at baseline and post-treatment.

Eating disorders are serious mental illnesses associated with significant morbidity and high relapse rates. Patients are at especially high risk of relapse after leaving structured treatment (e.g., hospitalization). Adjunct interventions targeting patients' motivation and participation in treatment at these times may help patients recover from eating disorders. Project HEAL is a non-profit organization whose mission is to reduce suffering caused by eating disorders, and they have recently developed two adjunct, mentorship-based interventions for patients in recovery. In the peer mentorship condition, individuals meet weekly with a peer mentor who has previously recovered from an eating disorder in order to discuss symptoms and coping strategies. In the social support mentorship condition, individuals meet weekly with a social support mentor who has not personally struggled with an eating disorder in order to engage in activities unrelated to the eating disorder. The aim of the current study is to evaluate the feasibility and efficacy of this intervention. The design of the study is a three-arm randomized controlled trial comparing peer mentorship, social-support mentorship, and wait-list control conditions. Participants in the study will be randomized to one of the three conditions for six months. Wait-list participants will subsequently receive either type of mentorship. Participants will complete assessments of their eating disorder symptoms at baseline, monthly throughout the course of the study, and one year after beginning the study. Outcomes will be compared between groups.

Eligibility Criteria:
Inclusion Criteria:

* Current or past 6 months AN, BN, or BED
* Recent (within 6 months) discharge from structured treatment
* Involved in outpatient treatment at an appropriate level of care
* Medical stability
* Access to smart phone or computer to complete study assessments

Exclusion Criteria:

* Evidence of needing specialized treatment for another medical or mental health condition
Postoperative Pain Intensity After Pulpotomy

Introduction: This study aimed to compare postoperative pain rates following sodium hypochlorite (NaOCl) and KTP laser-assisted pulpotomy treatments in permanent teeth with deep caries, and symptomatic irreversible pulpitis. Methods: Ninety patients complaining of permanent teeth pain due to symptomatic irreversible pulpitis were randomly divided into 3 equal groups. Preoperative pain levels were recorded. After the initial bleeding control was achieved with saline, complete hemostasis was achieved by applying saline (control group), 2.5% NaOCl, or KTP laser according to randomly determined patient groups. Patients were asked to mark their pain level on the visual pain scale at the 6th, 24th, 48th, and 72nd hours, and 7th and 30th days depending on the severity of the pain. The permanent restoration was completed after 7 days. Results: According to the present study, the statistical difference between the groups in terms of preoperative pain and percussion pain levels was insignificant.

There was no significant difference between the groups in terms of demographic data. The postoperative pain level of the KTP laser group was significantly lower at the 6th hour compared to the saline group. There was no significant difference between the groups in terms of postoperative pain level at other time intervals. The greatest pain scores occurred in all groups at 6th hour. Conclusions: KTP laser can be preferred primarily in reducing postoperative pain in pulpotomy treatments. KTP laser or NaOCl assisted pulpotomy can be an effective treatment for pain reduction in permanent teeth with symptomatic irreversible pulpitis.


Eligibility Criteria:
Inclusion Criteria:

* The patient should be ≥ 18 years old, a single tooth in every patient
* Must be signs of irreversible pulpitis, such as persistent pain that begins spontaneously and/or is exacerbated by cold. This situation should be repeated with the cold test.
* Irreversible pulpitis diagnosed, with or without symptomatic apical periodontitis
* No systemic disease
* Should give a positive response to electrical and thermal tests
* Must be the opposite tooth.
* The tooth is restorable, probing pocket (3mm) depth, and mobility are within normal limits

Exclusion Criteria:

* Presence of allergies
* Using analgesics in the last 12 hours or antibiotics in the last 1 week before the procedure.
* Presence of swelling, palpation pain or sinus tract before treatment, root fracture or crack.
* Failure to control bleeding within 6 minutes,
* Presence of bruxism or open apex.
* Insufficient bleeding after pulp exposure
* Observation of advanced canal calcification
* Presence of internal or external root resorption.
Search for Prognostic Factors Associated With Better Survival in Refractory Cardiac Arrest

Through this retrospective observational study (over 4 years; period analysed: 1st January 2011 to 31st December 2014), we looked for prognostic factors associated with better survival in refractory cardiac arrest by:

* assessing the overall survival rate
* evaluating the frequency of intra et extra-hospital events and by comparing these with the survival rate
* studying no flow, low flow, rhythm at initial management, troponinemia, lactatemia and blood pH in the different groups.


Eligibility Criteria:
Inclusion Criteria:

* Patients with in-hospital or out-of-hospital refractory CA who underwent ECLS

Exclusion Criteria:

* CA occurring during cardiac surgery
* Age \> 75 years or \< 18 years
The Effect of Breakfasts Varying in Protein Source on Appetite and Energy Intake

Over the last decades, changes in the diet and lifestyle have led to overall energy imbalance becoming commonplace and the emergence of an obesity epidemic with more than 1.6 billion adults being overweight.

Consumption of foods that can affect appetite by increasing satiety could regulate the total energy intake and thus body weight. There is data suggesting that the macronutrient composition of the foods and especially protein content may have a potent role on satiety. However, the type of protein appears to play a role in satiety possibly due to the different balance of the amino acid profile.

The research project is dedicated to identify the source (animal or plant) and the optimized protein quantity needed to accelerate satiation, suppress appetite and extend satiety until hunger appears again.

It is hypothesized that the consumption of animal derived protein-enriched meals will induce a reduction in hunger through the impact on gut hormones and peptides that are closely related to the short-term regulation of food intake.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males
* Age range 18-50 years
* Normal weight and overweight people as classified by BMI:20-29.9 kg/m2 (inclusive).
* Weight stable (within 3 kg) two months prior to study inclusion
* Understanding English well and feeling comfortable speaking it

Exclusion Criteria:

* Dietary protein consumption \>25% energy from protein
* Had surgery in the previous 12 months
* Have suffered a myocardial infarction or stroke at any time
* Suffer from any blood-clotting disorder or prescription of any medication affecting blood clotting
* Suffer from any metabolic disorders (e.g. diabetes, metabolic syndrome or hypertension)
* Any requirement to take long-term medication, especially those active on the gastro-intestinal tract or for cardio-vascular disease
* Any dietary restrictions or recently/currently on a weight reducing diet
* Irregular eating patterns or not regularly consuming breakfast
* Food allergies (e.g. milk protein allergies) or intolerances (e.g. lactose)
* Use of medication which affects food intake or behaviour (e.g. anti-depressants)
* Use of medication likely to affect taste, smell or appetite
* Eating restraint based on the three Factor Eating Questionnaire
* Use of any protein supplements
* A history of alcohol or drug misuse (the average daily number of units of alcohol considered as acceptable is 2-3 units women; 3-4 units men
* Smoking
* Athletes in training (\>10 h exercise/week)
* Female that is breast-feeding, pregnant, or if of child-bearing potential and are not using effective contraceptive precautions
* Involvement in a study involving an experimental drug/medication within 3 months prior to entry of this study
* Blood pressure \> 160/90 mmHg
* Vegan or Vegetarian
* Glucose \> 6 mmol/L
* Gamma glutamyl transpeptidase (liver enzymes) \> 1.9 μkat / L
* Alanine aminotransferase \> 1.1 μkat / L
* Cholesterol \> 6.5 mmol/L
* Triglycerides \> 2.0 mmol/L